Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Ocular Therapeutix (OCUL) reported a Q3 loss of $0.26 per share, missing the Zacks Consensus Estimate of a $0.23 loss. This is an improvement from the $0.51 loss per share a year ago.
November 14, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ocular Therapeutix reported a Q3 loss of $0.26 per share, missing the expected loss of $0.23. This is an improvement from the previous year's $0.51 loss.
The reported loss per share of $0.26 was worse than the expected $0.23, which is likely to negatively impact the stock price in the short term. However, the loss is an improvement from the previous year's $0.51, which may mitigate some negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100